{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:46:19Z","timestamp":1791920779797,"version":"4.3.4"},"reference-count":106,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite many recent advances in treatment options, acute myeloid leukemia (AML) still has a high mortality rate. One important issue in optimizing outcomes for AML patients lies in the limited ability to predict response to specific therapies, duration of response, and likelihood of relapse. With evolving genetic characterization and improving molecular definitions, the ability to predict outcomes and long-term prognosis is slowly improving. The majority of the currently used prognostic assessments relate to molecular and chromosomal abnormalities, as well as response to initial therapy. These risk categories, however, do not account for a large amount of the variability in AML. Laboratory techniques now utilized in the clinic extend beyond bone marrow morphology and single gene sequencing, to next-generation sequencing of large gene panels and multiparameter flow cytometry, among others. Other technologic advances, such as gene expression analysis, have yet to demonstrate enough predictive and prognostic power to be employed in clinical medicine outside of clinical trials, but may be incorporated into the clinic in the future. In this review, we discuss the utility of current biomarkers, and present novel biomarker techniques and strategies that are in development for AML patients. Measurable residual disease (MRD) is a powerful prognostic tool that is increasingly being incorporated into clinical practice, and there are some exciting emerging biomarker technologies that have the potential to improve prognostic power in AML. As AML continues to be a difficult-to-treat disease with poor outcomes in many subtypes, advances in biomarkers that lead to better treatment decisions are greatly needed.<\/jats:p>","DOI":"10.3390\/ijms232314543","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T02:10:54Z","timestamp":1669169454000},"page":"14543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Role of Biomarkers in the Management of Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"23","author":[{"given":"Sara","family":"Small","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_3","unstructured":"Jaffe, E.S. (2001). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Iarc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"ref_6","unstructured":"Tallman, M.S., and Pollyea, D.A. (2021, September 08). AML (Version 3.2021). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: Biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Eguchi, M., Minami, Y., Kuzume, A., and Chi, S. (2020). Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines, 8.","DOI":"10.3390\/biomedicines8080245"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1097\/HS9.0000000000000583","article-title":"Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions","volume":"5","author":"Wouters","year":"2021","journal-title":"Hemasphere"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2174\/1568009620666200424145622","article-title":"Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation","volume":"20","author":"Becker","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH Inhibitors in AML-Promise and Pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.leukres.2012.03.019","article-title":"Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group","volume":"36","author":"Nomdedeu","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"639387","DOI":"10.3389\/fonc.2021.639387","article-title":"IDH1\/IDH2 Inhibition in Acute Myeloid Leukemia","volume":"11","author":"Cerchione","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","article-title":"Enasidenib: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.2020008211","article-title":"How I diagnose and treat NPM1-mutated AML","volume":"137","author":"Falini","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 Maintains the Leukemic State through HOX Expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: Molecular basis and clinical implications","volume":"23","author":"Falini","year":"2009","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: From bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute\/Medical Research Council report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.189886","article-title":"NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents","volume":"103","author":"Prata","year":"2018","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: Current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"ref_38","first-page":"68","article-title":"Gemtuzumab Ozogamicin: Back Again","volume":"10","author":"Selby","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., Mazzone, C., Niscola, P., Cesini, L., Abruzzese, E., and de Fabritiis, P. (2021). CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers, 13.","DOI":"10.3390\/cancers13133214"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"ref_43","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: Results of a multicenter phase 3 study","volume":"115","author":"Lowenberg","year":"2010","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/10428194.2021.1876869","article-title":"Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all \u2018non-adverse\u2019 risk AML","volume":"62","author":"Ladha","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood.2022016593","article-title":"Revealing the dark secrets of TP53-mutated AML","volume":"140","author":"Hasserjian","year":"2022","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/bloodadvances.2021005859","article-title":"TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms","volume":"6","author":"Schimmer","year":"2022","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/JCO.2022.40.16_suppl.7020","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3324\/haematol.2019.218453","article-title":"Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Maslah","year":"2020","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Brecqueville","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Trouplin","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2005.10.033","article-title":"Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family","volume":"369","author":"Fisher","year":"2006","journal-title":"Gene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12185-018-2563-7","article-title":"Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms","volume":"110","author":"Asada","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","article-title":"Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations","volume":"116","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12935-021-02233-y","article-title":"Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia","volume":"21","author":"Fan","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_70","first-page":"60","article-title":"ASXL1 Gene in AML","volume":"47","author":"Hurtado","year":"2021","journal-title":"J. Assoc. Genet. Technol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","article-title":"The role of ASXL1 in hematopoiesis and myeloid malignancies","volume":"76","author":"Asada","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2018893982","article-title":"RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1","volume":"134","author":"Mill","year":"2019","journal-title":"Blood"},{"key":"ref_74","first-page":"145","article-title":"The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies","volume":"43","author":"Yokota","year":"2020","journal-title":"Mol. Cells"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/leu.2016.207","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_77","first-page":"325","article-title":"Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis","volume":"19","author":"Jalili","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data from Nine International Cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.17336","article-title":"Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): Results from an International Collaborative Study","volume":"192","author":"Kayser","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/leu.2013.198","article-title":"Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome","volume":"28","author":"Chilton","year":"2014","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano","year":"2012","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk without NPM1 Mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease with Survival Outcomes in Patients with Acute Myeloid Leukemia","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cBiTE out of ALL\u201d: Blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/bloodadvances.2020003727","article-title":"Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zhu, Y.-M., Wang, P.-P., Huang, J.-Y., Chen, Y.-S., Chen, B., Dai, Y.-J., Yan, H., Hu, Y., Cheng, W.-Y., and Ma, T.-T. (2017). Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance. J. Transl. Med., 15.","DOI":"10.1186\/s12967-017-1279-4"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"Hovestadt","year":"2019","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/s41375-021-01338-7","article-title":"Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression","volume":"35","author":"Stetson","year":"2021","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"826768","DOI":"10.3389\/fonc.2022.826768","article-title":"Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia","volume":"12","author":"Wiatrowski","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Yang, X., Wong, M.P.M., and Ng, R.K. (2019). Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184576"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13148-015-0153-6","article-title":"DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia","volume":"7","author":"Lin","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/atm.2019.11.122","article-title":"DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients","volume":"7","author":"Hu","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13148-022-01242-6","article-title":"A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel","volume":"14","author":"Folta","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/JLB.5A0220-676RR","article-title":"Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia","volume":"107","author":"Lin","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10032","DOI":"10.1200\/JCO.2021.39.15_suppl.10032","article-title":"Correlation of ex vivo drug sensitivity with clinical response in pediatric AML","volume":"39","author":"Kita","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Dowling, P., Tierney, C., Dunphy, K., Miettinen, J.J., Heckman, C.A., Bazou, D., and O\u2019Gorman, P. (2021). Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. Proteomes, 9.","DOI":"10.3390\/proteomes9040042"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1074\/mcp.RA120.002169","article-title":"A Proteomic Approach to Understand the Clinical Significance of Acute Myeloid Leukemia-Derived Extracellular Vesicles Reflecting Essential Characteristics of Leukemia","volume":"20","author":"Kang","year":"2021","journal-title":"Mol. Cell. Proteom."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-022-09367-9","article-title":"Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML","volume":"19","author":"Gosline","year":"2022","journal-title":"Clin. Proteom."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:26Z","timestamp":1760145866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":106,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijms232314543"],"URL":"https:\/\/doi.org\/10.3390\/ijms232314543","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}